# Fujian Luyan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fujian-luyan

- Industry: Pharmaceuticals
- Headquarters: Xiamen, China
- Website: www.luyan.com.cn
- Total disclosed funding: $22M
- Latest round: Series B (Jun 29, 2010)
- Investors on record: 2

## About

Fujian Luyan is a pharmaceutical company dedicated to the development and manufacturing of generic medications and innovative drug formulations, primarily targeting chronic illnesses and infectious diseases.Founded in 1992, Fujian Luyan is headquartered in Xiamen, China, and specializes in pharmaceutical development. The firm has completed a total of 5 deals, with its most recent funding being an IPO on January 28, 2016, raising RMB 597.73 million. Jinxiang Wu leads the company as CEO.Luyuan Pharmaceutical Co., Ltd. focuses on developing and manufacturing a wide range of pharmaceutical products, including therapeutic agents for chronic illnesses, infectious diseases, and pain management. Their offerings aim to improve patient outcomes through accessible and affordable treatment options for hospitals, pharmacies, and healthcare providers across Asia, Europe, and North America, adhering to international quality standards.In the most recent fiscal year, 2020, Fujian Luyan reported a revenue of CNY 2,248,082,001.90 and an EBITDA of CNY 87,736,965.30, generated through direct sales and partnerships with healthcare institutions, enabling effective supply chain management and competitive pricing strategies.Following its IPO in January 2016, where RMB 597.73 million was raised by selling 32.05 million shares at RMB 18.65 per share on the Shenzhen Stock Exchange, Fujian Luyan is focused on expanding its product line and entering new markets. The company is developing new pharmaceutical products aimed at further addressing chronic and infectious diseases, with plans to enhance its presence in markets throughout Asia and Europe by 2025.

## Funding rounds

- Series B, Jun 29, 2010, $19M — CCB International Asset Management
- Series A, Jul 28, 2009, $2.9M — Red Bridge Capital

## Investors

- Red Bridge Capital (https://capitalatlas.ai/funds/red-bridge-capital) — Series A
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series B